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RELEASING HORMONE DEFICIENCY USING RUNS OF HOMOZYGOSITY 
IN OUTBRED FAMILIES 
 
ANNA KUTATELADZE 
 
ABSTRACT 
Background: Isolated GnRH Deficiency (IGD) is a rare Mendelian disorder, 
characterized by absent puberty and infertility. Over 30 causal IGD genes have been 
discovered, yet only 30-35% of IGD cases have a proven genetic etiology, highlighting 
the importance of new discovery methods. Homozygosity mapping, traditionally used to 
detect autozygous segments in inbred populations, has recently proven useful for gene 
discovery in outbred populations.  
Methods: Strict quality control (QC) metrics for the SNP genotyped cohort and controls 
were used. Overall, 653 European IGD probands and 1,911 European controls remained. 
After pruning, 206,012 SNPs remained. Runs of Homozygosity (ROH) were found and a 
burden analysis was performed. Areas of known IGD genes, Expression Quantitative 
Trait Loci (eQTLs) of known genes and novel regions predicted to be associated with 
IGD were explored.  
Results: While there was no statistical difference between the ROH burden in cases vs. 
controls, there was an unexpected trend towards a greater burden in the controls. Of the 
known gene locations and their eQTL regions, there was a trend in cases having a higher 
representation of ROHs within these regions. Four ROH regions unique to cases only 
  vi 
were also discovered. None of the individuals had a variant in the coding genes found in 
these regions. 
Conclusions: SNP markers are found in coding regions and non-coding regions. This 
allows for a preview of potential disease causing variation in the non-coding region. Even 
though no coding gene of interest was found, the non-coding parts of the identified 
regions are of significant interest. 
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INTRODUCTION 
Isolated Gonadotropin Releasing Hormone Deficiency  
Isolated Gonadotropin Releasing Hormone (GnRH) Deficiency (IGD) is a mendelian 
disorder that results from the failure of the secretion or action of GnRH neurons. This 
failure disrupts the normal functioning of the hypothalamic-pituitary-gonadal (HPG) axis.  
The HPG axis (Figure 1), known 
as the reproductive axis, is an 
integrated endocrine signaling 
system that hormonally connects 
the hypothalamus, the anterior 
pituitary, and the gonads in both 
a ‘feed forward’ stimulatory 
system and a ‘feedback’ 
inhibitory system that act 
together to provide the delicate 
balance required for reproduction 
to proceed in a timely and 
physiological fashion at the 
appropriate developmental time. 
Starting cranial to caudal on this 
axis, GnRH neurons in the 
hypothalamus secrete pulsatile GnRH1, a decapeptide hormone, into the hypophyseal 
Figure 1: Kisspeptin + Hypothalamic-Pituitary-
Gonadal Axis - Classic HPG axis plus kisspeptin. 
Although not discussed in this paper, kisspeptin released 
by kisspeptin neurons and their receptor GPR54 
(KISS1R) were found by our group (Seminara 2003) to 
be essential for normal GnRH neuronal function.  
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portal capillaries that flow through the anterior pituitary (Amoss 1971; Matsuo 1971). 
From the hypophyseal portal capillaries, GnRH1 is able to bind to GnRH1 receptors 
(GnRHR1) on the anterior pituitary’s gonadotrope cells. GnRHR1 is a 7-membrane-
spanning, G-coupled protein receptor (GPCR) which activates the phosphatidylinositol-
calcium secondary messenger and leads to the activation of protein kinase C (PKC) and 
eventually the physiological release of luteinizing hormone (LH) and follicle stimulating 
hormone (FSH) (Stojilkovic 1995; Naor 2000). Two genes for GnRH exist in mammals, 
GnRH1 and GnRH2, which bind to their respective receptors, GnRHR1 and GnRHR2. 
Not much, however, is known about the function of GnRH2 or its receptor other than that 
it appears to be a ‘pseudogene’ that is not transcribed in humans (Desaulniers 2017; Neill 
2004). Therefore, this paper will refer to GnRH1 simply as GnRH and GnRHR1 as 
GnRHR.  
LH and FSH are dimeric glycoprotein hormones that then travel through the 
vasculature and bind to their 
receptors on the ovaries in 
females and testes in males. 
FSH stimulates 
gametogenesis, i.e. follicular 
development in females and 
spermatogenesis in males, as 
well as the secretion of the 
dimeric gonadal protein 
 
Figure 2: GnRH neuronal migration in a mouse model. 
The black dots represent GnRH neurons and the picture is 
divided into their location at embryological day 11-16. The 
GnRH neuron originates with the vomeralnasal organ (vno) 
and travels along the vomeralnasal and olfactory nerve to the 
olfactory bulb (ob) and eventually, by day 16, most GnRH 
neurons are located in the preoptic area (poa) of the 
hypothalamus. (Schwanzel-Fukuda 1989)  
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hormone, inhibin, that restrains FSH secretion in both females and males. LH stimulates 
the release of androgens from the gonads of both sexes: androgens that will eventually be 
converted to the sex steroid hormones estrogen (E) in females and testosterone (T) in 
males. These sex steroid hormones and inhibin together provide a negative feedback loop 
to restrain the output of the anterior pituitary gonadotropes of the HPG axis. As their 
levels increase, they inhibit gonadotrope secretion of LH and FSH and the secretion of 
GnRH from the GnRH neuron (Vadakkadath 2005).  
The failure of the HPG axis in IGD most frequently occurs due to genetic defects 
within the hypothalamic GnRH neurons. Consequently, these patients typically present 
with hypogonadotropic hypogonadism characterized by low levels of gonadotropins (LH 
and FSH) and low (i.e. pre-pubertal) levels of sex steroids (E and T). In 1989, 
Schwanzel-Fukuda et al. found that GnRH neurons originate in the medial olfactory 
placode, i.e. extramural to the CNS, and subsequently migrate along the vomeronasal and 
olfactory nerves into the brain at the cribriform plate. From there, they proceed into the 
pre-optic area and eventually to the mediobasal area of the hypothalamus (Figure 2).  
There, the mature GnRH neuronal processes project into the hypophysial portal 
capillaries of the median eminence and secrete GnRH, which is eventually delivered by 
these capillaries to the anterior pituitary gland where they regulate pituitary hormone 
release from the gonadotropes (Schwanzel-Fukuda 1989, Wierman 2012). 
IGD is heterogeneous in its phenotypic presentation. IGD patients can present 
with either a normal sense of smell (normosmia), known as normosmic isolated 
hypogonadotropic hypogonadism (nIHH), or they can present with the loss of the sense 
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of smell (anosmia), known as Kallmann Syndrome (KS). nIHH is prevalent in about 40% 
of IGD cases while KS accounts for about 60% of IGD cases (Balasubramanian 2011). 
IGD is a rare disease, with Kallmann Syndrome affecting 1:125,000 females and 
1:30,000 males (Laitinen 2011). In addition to this difference in ability to smell, IGD 
patients also vary in severity and timing of reproductive defects and may or may not 
present with a variety of other non-reproductive phenotypes (Balasubramanian 2011). 
Kallmann Syndrome (KS) was first documented in 1944 by Franz Josef 
Kallmann, an American geneticist who reported three different families affected with KS 
and, additionally, first noted normosmic IGD patients (Kallmann 1944). His observations 
thus first suggested a genetic etiology for IGD. In 1986, Ballabio et al. reported a boy 
with 3 different genetic diseases: KS, chondrodysplasia punctate and X-linked ichthyosis. 
His karyotype analysis and positional cloning revealed a large deletion on the X 
chromosome (Xp.22.3), inherited from the proband’s mother. This study, along with 
others, defined this deletion that encompassed three genes—KAL1 (now known as 
ANOS1), ARSE, and STS—that respectively caused the boy’s KS, chondrodysplasia 
punctata, and ichthyosis, thus making ANOS1 the first Kallmann Syndrome gene 
(Ballabio 1986; Bick 1989).  
In 1989, Schwanzel-Fukuda et al, discovered that the GnRH neurons did not 
migrate normally in individuals with KS (Schwanzel-Fukuda 1989). In patients with the 
KS mutation, this migration is halted at the level of the cribiform plate, thereby affecting 
olfactory sensing and GnRH neuronal function. In 1991, ANOS1 (KAL1) was shown to be 
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involved in neuronal cell adhesion and axonal path-finding thus officially establishing it 
as a KS-causing gene due to the inhibition of GnRH neuronal migration (Franco 1991).  
As insightfully 
written by Franz Josef 
Kallmann in his 1944 article, 
“[t]here is no reason to 
assume that it must always 
be the same mechanism… or 
the same gene that causes the 
disease….” (Kallmann 
1944). This quote 
emphasizes the genetic 
complexities of IGD that 
underlie our current understanding. Since the discovery of ANOS1 (KAL1) in 1991, over 
30 new genes have been shown, when mutated, to be sufficient to cause IGD. (Stamou 
2015).  Even with these advances in gene discovery, as shown in Figure 3, only about 30-
35% of all IGD cases have a proven genetic etiology (Stamou 2015). This observation, 
along with the complexities and puzzles of puberty initiation itself, as shown in a special 
edition of Science Magazine that lists pubertal initiation as a top 125th unanswered 
scientific question (Science, July, 2005), implies that there are many more genes left to 
discover to have a clearer understanding of the pathophysiology behind IGD and 
ultimately the physiology behind puberty initiation.  
Figure 3: Methods Used in IGD Gene Discovery.  This 
includes newer, faster strategies through new generation 
sequencing including whole exome sequencing and whole 
genome sequencing that are revolutionizing genetic 
discovery. (Stamou 2015) 
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Among the 30+ genes we now associate with IGD, there are two main aspects of 
the GnRH neuronal 
function that can be 
impaired and cause 
the disease (Figure 4). 
First, a genetic 
mutation in a 
particular gene, such 
as ANOS1 (KAL1), 
can cause a 
neurodevelopmental 
failure that prevents 
normal GnRH 
neuronal migration. 
Second, a genetic mutation in a particular gene can cause a neuroendocrine failure, 
thereby preventing proper signaling of GnRH, such as Kisspeptin/GPR54 
(KISS1/KISS1R). Some IGD-causing genes have also been shown to participate in both 
phenotypes of IGD (anosmic/normosmic) including Prokineticin 2/Prokineticin 2 
Receptor (PROK2/PROKR2). Along with their complex regulatory functions, these IGD 
genes also exhibit variable penetrance/expressivity within families and among different 
families with the same mutations (Pitteloud 2007). Other phenotypes that share at least 
some genetic links to IGD are shown in Table 1 below.  
Figure 4: The Complexity of GnRH Migration and Signaling. 
GnRH neurons form from neuroectoderm and evidence also 
points to a subset forming from neural crest (Whitlock 2003). 
This picture shows on the left genes involved in 
neurodevelopment that when mutated, cause a failure in GnRH 
migration. This picture shows on the right genes involved in 
neuroendocrine function and when mutated, impair GnRH 
signaling. In the center of the picture are genes involved in both 
processes (Stamou 2015).  
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Homozygosity mapping 
Homozygosity mapping is a genetic discovery tool (classified under endogamy in 
Figure 3) that traditionally looks at haplotype blocks (a group of genes inherited from a 
single parent) passed down in consanguineous families such that an affected individual’s 
consanguineous parents will each be a carrier of the same recessive gene mutation(s) that 
is/are identical by descent (IBD). This mutation will then be passed down to their 
affected child so that this child is homozygous for the recessive mutated gene (Ceballos 
2018). As seen in Figure 5, the grandmother of the affected child’s parents is a carrier for 
the recessive mutation. Despite crossing-over events, the majority of her original 
haplotype block, that includes the mutated allele, is passed down to both of the affected 
child’s parents, and eventually, passed down in a homozygous manner to their affected 
Table 1: Phenotypes Genetically Related to IGD 
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child (Hildebrandt 2009).  
Homozygosity mapping, therefore, allows for the discovery of homozygous 
mutations in recessive genes that are passed down by both of the affected individual’s 
parents and the mutations are said to be IBD. These regions are said to be autozygous. 
The power in this method lies in the fact that detection of these haplotype blocks relies on 
identified linkage markers that are scattered throughout the genome with a majority 
(~80%) spanning the non-coding region. Botstein first described the use of these 
polymorphic marker loci in 1980 (Botstein 1980) that could serve as ‘genome addresses’ 
that could be used to identify physical positions on chromosomes. These identifiers 
include microsatellites and single nucleotide polymorphisms (SNPs) (Ball 2010).  Bolino 
et al., in 1996, were among the first people to use long consecutive stretches of 
homozygous markers in a consanguineous family to predict regions of autozygosity 
(Bolino 1996). This phenomenon is known as a run of homozygosity (ROH). Between 
1995 and 2003, almost 200 studies were published that used this ‘homozygosity 
mapping’ in consanguineous families to discover rare recessive mutated genes (Botstein 
2003). In our center, an IGD gene mutation in GPR54 (KISS1R) was found in a 
Figure 5: Traditional Homozygosity Mapping (Hildebrandt 2009) 
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consanguineous family in a haplotype block that was 1.06 Mb long and located on 
chromosome 19p13.3 (Seminara, Crowley 2010).  
Empirical studies have shown that there is a burden of homozygous deleterious 
variants in regions of homozygosity (ROH) compared to non-deleterious variants 
(Szpiech 2013). This observation increased the importance in detecting these ROHs, not 
just in consanguineous families, but also within non-consangineous families. Given the 
size of the human population, we are all inbred to some degree and therefore ROHs 
should be seen in all individuals. The typical size of a ROH in a consanguineous family, 
however, is relatively 
large (Figure 5) when 
compared to an outbred 
population (Figure 6) 
since the common 
ancestor of the 
consanguineous parents is 
comparatively recent 
(Ceballos 2018). ROHs, however, are seen in the general population and, on average, an 
individual’s genome will encompass around 10 ROHs (McQuillan 2008). The amount of 
ROHs in a population is dependent on the effective population size (size of the 
reproductively capable population), where smaller populations tend to have more ROHs 
(Ceballos 2018). As next generation sequencing techniques have improved over time, a 
clearer and denser picture of the genome is emerging that allows for improved detection 
 
Figure 6: Homosygosity mapping in an outbred family. 
Modeled after pedigree from Hildebrandt et al. 2009 
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of these ROHs in non-consanguineous families. In 2002, the International HapMap 
Project identified over 3 million common SNP variations in 269 individuals from 4 
populations in its phase 1 and 2 studies. In phase 3, 1,301 individuals were analyzed from 
11 different populations, which allowed high density single nucleotide polymorphism 
(SNP) arrays to become more widely available (International HapMap Constortium 
2007).  
These advances have, in turn, enabled researchers to make greater use of 
homozygosity mapping in outbred populations for gene discovery, including Keller et al., 
who showed an increased burden of ROHs in schizophrenia when compared to a control 
population (Keller 2012).  Since IGD is a rare reproductive disorder, it would therefore 
be predicted to be under high negative selection (or purifying selection). Therefore, it 
might be expected that the disease risk alleles leading to IGD would be enriched for 
recessive mutations. Hence, homozygosity mapping should be an ideal tool to help 
uncover some of these recessive disease risk alleles (Keller 2012; Charlesworth 2009). 
Furthermore, SNP arrays also have the advantage of covering a large majority of the non-
coding regions of the genome allowing this technique to theoretically detect potential 
modifier regions within the non-coding transcript that have previously been unassociated 
with IGD.   
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Specific Aims 
Specific aims of the following thesis are: 
1. Determine whether there is an increased burden of areas of autozygosity in 
unrelated probands of European descent when compared to control individuals 
of European descent. 
a. If validated, it would imply that the more ROHs an individual has, the 
higher risk they are of inheriting IGD. Inbred individuals, therefore, 
would have an increased risk for IGD when compared to outbred 
individuals since inbred individuals have larger runs and numbers of 
ROHs. 
2. Investigate whether there are regions of shared SNPs (ROH) that harbor novel 
homozygous mutations in known genes or regulatory regions of these known 
genes that contribute to IGD. 
a. By using homozygosity mapping and pinpointing known gene 
locations and regulatory regions of these known genes, there is a 
potential for uncovering novel mutations within these areas. 
3. Investigate whether there are regions of shared SNPs (ROH) that harbor novel 
homozygous mutations in novel genes or novel regulatory regions that 
contribute to IGD. 
a. By using homozygosity mapping, there is a potential for uncovering 
novel genes, novel pseudo genes, novel enhancer/repressor regions, 
novel RNAs or other novel transcripts within the coding or non-coding 
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region that are currently unknown to be associated with IGD but are 
found to be causal of IGD.  
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METHODS 
Case Cohort  
All participants had been recruited with approval from the Institutional Review Board of 
Partners Healthcare over a 40-year period and had given their informed consent to 
participate in a genetic study to understand the causes of hypogonadotropic 
hypogonadism and the genetics of human reproduction. 2,409 individuals were selected 
for genotyping analysis as they had a reproductive phenotype or were family members of 
an individual who exhibited a reproductive phenotype. SNP genotyping was performed at 
the Broad Institute from genomic DNA extracted from peripheral blood samples. For this 
analysis, the only reproductive phenotype considered was hypogonadotropic 
hypogonadism (nIHH or KS).  
Control Cohort 
2,199 controls from The Schizophrenia Psychiatric Genome-Wide Association Study 
were provided by Benjamin Neale, PhD. They also had undergone standard QC metrics 
and the Broad Institute as seen in the Psychiatric GWAS Consortium 2011.   
SNP Genotyping: Psychiatric predisposition microarray 
All SNP genotyping was performed at the Broad Institute from genomic DNA extracted 
from peripheral blood samples. Since IGD is a brain-based disease, the PsychArray-24 
SNP platform (V1.1 and B) from Illumina was used for genotyping. This PsychChip 
includes ~271,000 proven tag SNPs from the Infinium HumanCore-24 Beadchip, 
~277,000 markers from the infinium Exome-24 BeadChip and ~50,000 markers 
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associated with common psychiatric disorders (i.e. brain-based disease). The V1.1 
version of the SNP platform includes 22,196 new SNPs not seen in the B version and 
4,832 SNPs that were present in the B version that are missing from the V1.1 version. 
1,044 individuals were genotyped using the V1.1 version while 1,365 individuals were 
genotyped using the B version. For this analysis, only shared SNPs between the two 
platforms were used. Three genotype calling algorithms were used to call variants and 
include Birdseed from the Birdsuite software, Autocall from the GenCall software, and 
Zcall.  Birdseed and Autocall both excel in calling common variation (Minor allele 
frequency (MAF)>0.01) while Zcall was designed specifically for calling rare variants 
(MAF<0.01). 
Audit of Cases 
Of the 1,403 probands with either nIHH or KS (732/1403 with nIHH and 671/1,403 with 
KS) whose DNA samples had all undergone SNP genotyping using the PsychChip at the 
Broad Institute, every 20th individual was selected (72/1,403 individuals with 39/72 
individuals having an nIHH phenotype and 33/72 individuals having a KS phenotype) to 
undergo an extensive records review which included evaluating and confirming each 
individual’s documented sex, diagnosis, age, clinical characteristics that led to their 
diagnosis, including their hormone levels, pubertal development, imaging and smell 
phenotype, and any other recorded phenotype that had been given. The quality of the 
recorded phenotyping information was then assessed. If needed, a cases status was 
updated prior to case vs. control analysis.  Only one individual’s phenotype was updated.  
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Sample Processing and Initial Quality Control 
Once genotyping data was returned from the Broad Institute’s Core, every individual was 
validated for his or her correct identification number, correct sex, correct parent 
identification numbers if an individual’s parents are in the study, and correct phenotype 
status (KS/nIHH phenotypes being the only individuals listed as affected). Everyone else, 
including individuals with 
other reproductive phenotypes, 
were labeled as unaffected for 
the purposes of this study. 
Once complete, individuals 
were removed who did not 
have a clear SNP call in each of 
the three calling algorithms. 
Since two versions of the 
PsychChip were used, pre-
quality control measures, as well as some QC measures, were performed on each of the 
versions separately before merging them (Figure 7). PLINK (Purcell 2007) was used to 
perform all QC analysis, aside from principal component analysis (PCA), where 
Population Structure Inference in KING (Manichaikul 2010) was used. Of the 1,044 
individuals genotyped on the V1.1 version of the PsychChip, 39 individuals did not pass 
all three calls and were removed, leaving 1,005 individuals. Of the 1,365 individuals 
genotyped on the B version of the PsychChip, 216 did not pass all three calls and were 
Figure 7: QC outline. The two columns under cases 
represent the two versions of the Illumina SNP chip used.  
1 
2 
3 
1 
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also removed, leaving 1,137 individuals. SNPs with a call rate of less than 97% were then 
removed from birdseed and autocall algorithms only (best suited for common variant 
calling) with an average of around 35,000 SNPs lost. Since Z-call performs ideally on 
rare SNPs (MAF<0.01), only the rare SNPs were kept on the Z-call algorithm before QC 
could be done. Individuals (n=4) with a call rate of less than 95% were also removed. 
Since birdcall and autocall perform more reliably on SNPs with MAF>0.01, they were 
subsequently merged together. SNPs from this merged data set with MAFs<0.01 (rare 
SNPs) were removed but kept as the only SNPs in the zcall calling algorithm. SNPs from 
the merged birdseed/autocall data set with a call rate of less than 97% were then removed 
from the merged birdseed/autocall data set and SNPs with a call rate of less than 97% in 
the zcall data set were removed from the zcall data. An average of 2,829 SNPs were 
removed between the two sets. 
Quality Control on merged calls 1 (Figure 7: Merge Calls 1) 
 Once all three calls were merged on each of the two PsychChip versions, QC was as 
follows: a) SNPs with a call rate < 95% were removed using PLINK --missing argument 
to provide a ‘missingness rate’ for each SNP through generation of an lmiss dataset. b) 
Individuals with a call rate of < 98% were removed again using PLINK --missing 
argument to provide a missingness rate for each individual through generation of an imiss 
dataset. c) Inbreeding coefficient was determined using PLINK’s --het argument to 
generate a .het text file. Individuals who fell out of the -0.2-0.2 frequency of 
heterozygosity (FHET) inbreeding metric range were then removed. d) The sex of each 
individual was confirmed using PLINK --check-sex argument. No SNPs remaining had a 
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call rate of less than 95%. Three individuals in the V1.1 version of the PsychChip and 
two individuals in the B 
version of the 
PsychChip did not pass 
the call rate greater than 
98% and were 
subsequently removed. 
Two individuals from 
the V1.1 version of the 
PsychChip and three 
individuals from the B 
version of the 
PsychChip fell outside the FHET for inbreeding coefficient range and were removed. 
Finally, 15 individuals were removed from the V1.1 version of the PsychChip and 101 
individuals were removed 
from the B version of the 
PsychChip for individuals 
that were either male but had 
an FHET Sex Determination 
Metric  >0.8 or were female 
but had an FHET Sex 
Determination Metric <0.4. Figure 9: Summary of QC. 
 
 
Figure 8: Example of FHET for SEX Determination Distribution 
After A Sex Check was Performed on Newer PsychChip. 
Distribution of FHET per individual. Traditionally, females with 
FHET less than 0.2 are considered to have passed the sex check but 
for our analysis, females with an FHET less than 0.4 were considered 
to have passed the sex check (circled in red) and males with an FHET 
greater than 0.8 were considered to have passed the sex check. The 
orange dots less than 0.4 that are not circled in red were males and did 
not pass the sex check and the orange dots greater than 0.8 were 
female and did not pass the sex check. 
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Traditionally, a female should have an FHET sex determination metric <0.2 but for this 
analysis, due to the distribution of the plot in Figure 8, individuals who were female with 
an FHET sex determination metric<0.4 passed the sex check (circled in red in Figure 8). 
A general summary of the QC process is seen in Figure 9.  
Quality Control on merged PsychChips and Controls (Figure 7:  Merge Calls 2 and 
3) 
The two different PsychChip versions had some SNPs that were located in the same 
location but given a slightly different name. Therefore, a list of SNP locations was 
generated with just one SNP name to represent that location. Thus, when these two 
SNPChip versions were merged, there was only one name for each SNP per location. 
Once the two SNPChip versions were merged using PLINK’s --bmerge argument, two 
multiallelic SNPs were removed and 553,926 SNPs remained with 1,996 total individuals 
that were either probands, family members of probands, or other non-IGD phenotype 
individuals from the IGD cohort. The Schizophrenia Psychiatric Genome-Wide 
Association Study Consortium controls were then merged with the IGD cohort using 
PLINK’s --bmerge argument. There were a total of 554,631 SNPs with 4,195 individuals. 
The QC at this step was as follows: a) SNPs with a call rate of < 95% were removed. b) 
Individuals with a call rate < 98% were removed. 120,083 SNPs had a call rate <95% and 
were removed, leaving 430,288 SNPs. All individuals passed with a call rate >98%.  
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PCA: European Population  
Principle component analysis was done using --pca 5 argument using the Population 
Structure Inference in KING (Manichaikul 2010). The merged IGD cohort and 
Schizophrenia Psychiatric Genome-Wide Association Study Consortium controls were 
merged with HapMap3 (International HapMap Constortium 2007) and coordinates that 
correlate with ethic SNPs that define African populations (ASW, LWK, MKK, YRI), an 
Indian population (GIH), a Mexican population (MXL), East Asian populations (CHB, 
CHD, JPT) and European populations (CEU, TSI) were determined. Figure 10 shows an 
example of the graphs used to define the European populations. Two different HapMap3 
populations define the Europeans, the Utah residence from Northern and Western 
European Descent (CEU) and the individuals from Tuscany, Italy that represent a 
Hapmap 3 Cases and Controls 
Figure 10: Representative Example of a Graph used to Define Different Ethnic Populations. The 
same coordinates are depicted with only the hapmap 3 individuals in the top left, the cases and controls 
together in the top right, the cases only in the bottom left, and the controls only in the bottom right. 
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Southern European Descent. As shown in Figure 10, the Hapmap 3 graph depicts the 
CEU population with red squares in the upper left corner and the TSI population below it 
with purple diamonds on the lower left side. As shown in the three other graphs, the 
majority of the cases as well as the controls are seen roughly equally between the 
Northern/Western European Population and the Southern European Population. European 
populations from the merged IGD cohort and Schizophrenia Psychiatric Genome-Wide 
Association Study Consortium controls were then extracted. Out of the 4,195 total 
individuals, 3,130 individuals were isolated as European with 1,219 individuals from the 
IGD cohort and 1,911 individuals from the Schizophrenia	  Psychiatric Genome-Wide 
Association Study Consortium controls. A new data set with only European IGD 
probands was created for this analysis (to minimize the influence of any population 
stratification) plus all the European Schizophrenia Psychiatric Genome-Wide Association 
Study Consortium controls. There were 653 European probands and 1,911 European 
Schizophrenia Psychiatric Genome-Wide Association Study Consortium controls. Hardy-
Weinberg Equilibrium (HWE) was then performed on the European dataset using 
PLINK’s --hardy argument and removing any SNPs that had a P<1e-7 and therefore 
would deviate from what would be expected in a normal population. 291 SNPs (115 of 
these SNPs had a MAF<1%) were removed that failed HWE, leaving 429,937 SNPs. 
Finally, a missingness by phenotype analysis using PLINK’s --test-missing argument was 
performed to remove any SNP that had a P<1e-7 and would therefore be under-
represented in either the controls or the cases and could result in false ROHs. 452 SNPs 
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failed the missingness by phenotype of P<1e-7 and were removed, leaving 429,485 
SNPs. 
ROH Calling Using European Only Cohort 
To remove SNPs in linkage disequilibrium (LD) with one another that would therefore be 
on the same haplotype block and cause false positives, PLINK’s pruning function was 
used. The general pruning method uses a window size of 50 SNPs that moves every 5th 
SNP. Two different pruning methods were used: i) pairwise-pruning which considers the 
given correlation between two SNPs. If there is a significant pairwise genotypic 
correlation between the two, the SNP with the lower MAF will be removed in order to 
preserve the SNP that would be present in the population at a higher frequency and will 
be more informative about the haplotype block it represents; ii) pruning using the same 
method as pairwise with the additional use of the variance inflation factor (VIF) which 
accounts for non-linear combinations of SNPs and is therefore a more stringent pruning 
method. VIF is 1/(1-R2) where  r2>0.5. Both pruning methods were performed using 
PLINK. The pairwise pruning was done using PLINK’s --indep-pairwise argument, 
removing 164,963 SNPs and leaving 264,522 SNPs. The pruning taking into account the 
additional VIF was done using PLINK’s --indep argument, removing 223,473 SNPs and 
leaving 206,012 SNPs. Runs of homozygosity (ROH) were found using PLINK’s --
homozyg argument and specifying for no heterozygous SNPs in a run, a minimum 
amount of 65 SNPs/run (Howrigan 2011), a minimum density of 50 kb SNPs (1 SNP 
every 50 kb) per run, overlapping ROHs matching by at least 95%, and finally, the 
maximum homozygosity gap between two SNPs in a run being 500kb, since larger 
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distances between two SNPs in a run could include areas such as the centromere in the 
chromosome. If two SNPs in a ROH have a distance larger than 500 kb between them, 
the ROH was broken into two different ROHs. Initial ROH analysis was performed on 
both the pairwise LD pruned dataset (33,054 ROH) and the VIF LD pruned dataset 
(34,893) to compare the two but due to the overall outperformance of the VIF LD 
pruning when compared to pairwise LD pruning, VIF LD pruning was eventually the 
only dataset used (Howrigan 2011). 
ROH Burden Analysis in the European Only Cohort 
A frequency histogram of the number of individuals with a specific number of ROHs was 
plotted in the European cases versus the European controls. An unpaired two-tailed T-test 
using GraphPad software was performed to determine if a significant result was achieved. 
The ‘Froh,’ or the proportion of the genome of an individual that is part of a ROH found 
by addition of the total length of all an individual’s ROH in kb divided by the total SNP-
mappable autosomal distance in our dataset of 2.97x106 kb (Keller 2012), of each 
individual was also determined and the average Froh in cases vs the average Froh in 
controls was calculated. An unpaired t test using GraphPad software was then performed 
to compare the average Froh in the cases vs. the average Froh in the controls. A 
histogram to visually assess the number of individuals with a certain length of ROH in 
cases vs. controls was also graphed using the VIF dataset only. 
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Homozygosity Mapping Analysis on Known Genes and their Predicted Regulatory 
Sites in the European Only Cohort 
All individuals’ ROHs were examined in the VIF LD pruned data to see if any ROHs 
overlapped with the locations of the 27 genes known to cause IGD when mutated 
(Balasubramanian 2003). The number of cases and controls with a run that spans a 
known gene were then recorded. Even though whole exome sequencing (WES) had been 
done on all of the SNP genotyped individuals in our cohort, there is a chance that a 
variant in a gene was missed. Therefore, if the location of a known IGD gene was found 
in a ROH of a case subject, that individual was queried for a variant in that gene. This 
step is also a good way to confirm the method used if we are able to uncover known 
homozygous mutations in individuals. The locations of significant cis-expression 
quantitative trait L\loci (cis-eQTLs) for the same 27 known IGD genes were found 
through GTEx’s Gene eQTL Visualizer (GEV) summarized using a heat map (GTEx 
Consortium 2017) that signify a potential regulatory region. A eQTL is marked by a SNP 
and is associated with the expression level of the target gene. A cis-eQTL is found less 
than 1 Mb away, either downstream or upstream, from the target gene’s transcription start 
site (GTEx Consortium 2017) while a trans-eQTL would be defined as a variant 5Mb 
away, either downstream or upstream, from the target gene (Nica 2013). A significant 
cis-eQTL in this study is defined as having a false discovery rate (FDR) of <5% and an 
absolute effect size, determined by effect of the alternate allele relative to the effect of the 
reference allele, greater than 0. The significance metric was relaxed for this study since, 
again, these locations were used to identify potential areas of interest and false positives 
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in this case are less concerning than false negatives. Locations of cis-eQTLs for this 
study were only analyzed if they were expressed in brain tissue or pituitary tissue since 
IGD is a neural disease and also related to the pituitary due to the neuroendocrine 
connection between the hypothalamus and the pituitary.  
Homozygosity Mapping Analysis in Novel Regions of the Genome in the European 
Only Cohort 
ROHs most likely to contain novel genes or regulatory regions were deduced by 
analyzing homozygous SNPs seen only in the cases and not in the controls in the VIF 
pruned data set. Statistically, the likelihood of 3 probands sharing a ROH not seen in 
controls is relatively high and as calculated by a two-tailed Fisher’s exact test. The P 
value for 3 probands sharing a unique region not seen in any controls is 0.017. On the 
other hand, the likelihood of 4 probands sharing a ROH not seen in controls becomes 
more significant. Using the same two-tailed Fisher’s exact test, the P value for this 
becomes 0.004. Therefore, only regions shared by 4 or more probands and no controls 
were analyzed as unique and potentially informative areas. These regions were then 
queried through the University of California Santa Cruz Genome Browser (Kent 2002) 
for coding genes and non-coding regulatory areas in these regions. Each proband that had 
a ROH that encompassed one of these unique regions was queried for a misssense or 
loss-of-function variants (frameshift mutations, insertions/deletions, or splice site altering 
mutations) with the variant having a MAF<10% in the gnomAD genome browser (Lek 
2016) to ensure low frequency in the unaffected population and with a depth score of >5 
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to ensure accurate readings in the coding genes within that region using Gemini: a 
flexible framework for exploring genome variation (Paila 2013).  
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RESULTS 
ROH Burden Analysis in the European Only Cohort 
The number of ROHs seen in the European probands (cases) only was 8,232 when 
pairwise LD pruning was applied and 8,713 when VIF LD pruning was applied. This 
means that on average, each proband had ~12.61 ROHs when pairwise LD pruning was 
applied and ~13.34 ROHs when VIF pruning LD pruning was applied. The total number 
of ROHs seen in the European controls was 24,822 when pairwise LD pruning was 
applied and 226,180 when VIF LD pruning was applied. This means that on average, 
each control had ~13.00 ROHs when pairwise LD pruning was applied and ~13.70 ROHs 
when VIF LD pruning was applied. Thus, there is no significant difference between the 
average ROHs per individual in cases vs controls.   
The frequency histogram of the number of individuals with a specific number of ROHs in 
the European probands (cases) vs. the European controls was then plotted in both the 
pairwise pruned data set and the VIF pruned data set, as shown in Figure 11, to visualize 
the distribution of each population. An unpaired two-tailed T-test was then performed for 
Figure 11: Frequency graph in European cases vs. European controls in both the pairwise pruned 
and VIF pruned data sets. P-value of the pairwise pruned cases vs. controls was 0.054 and p-value for 
the VIF pruned cases vs. controls was 0.024. 
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the cases vs. the controls using GraphPad software in both the pairwise LD pruned data 
set and the VIF LD pruned data set. The p-values for both were not significant at p<0.01 
with the pairwise LD pruned data set having a p-value of 0.054 and the VIF pruned data 
set having a p-value of 0.024. The average Froh of the cases was compared to the Froh of 
the controls, which takes into account not only the number of ROHs of the individuals, 
but also the length of these ROHs. The length corresponds to the amount of inbreeding an 
individual has in their family where inbred individuals have longer haplotype blocks and 
therefore a larger Froh. The average Froh of the cases in the pairwise LD pruned data set 
was 0.0064 and the average Froh of the controls in the pairwise LD pruned data set was 
0.0068. An unpaired T test using GraphPad software was then used to compare the two 
values and the two-tailed p value equaled 0.072 and was not significant at a p<0.01. The 
same calculation was performed on the VIF pruned data set. The average Froh of the VIF 
pruned cases was 0.0068 and the average Froh of the VIF pruned controls was 0.0072. 
The two-tailed p-value for the unpaired T-test was 0.089 and therefore also not 
significant at a p<0.01. A histogram was used to visually see the distribution of the sum 
of all ROHs per individual in cases versus controls in the VIF pruned data set depicted in 
 28 
figure 12. 
 
Homozygosity Mapping Analysis on Known Genes and their Predicted Regulatory 
Sites in the European Only Cohort 
The locations of 26 autosomal genes known to cause IGD (7 of them being more 
common causes) as per Balasubramanian 2003 (Balasubramanian actually lists 27 genes 
but ANOS1, previously known as KAL1, is located on the X chromosome, which was not 
analyzed in this study) were recorded. ROHs in the European cases and controls that 
overlapped with one of these known 26 genes were recorded as shown in Table 2. 
Figure 12: Histogram of Sum of All ROH Lengths  
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Since all individuals from the cases were whole exome sequenced, their genomes were 
queried for the known gene that was contained within one of their ROH. Two of the 
cases, (IDs: 47601 and 1661001), had a ROH encompassing a more common causal IGD 
gene, GNRHR. When these individuals were queried in GEMINI, each was found to carry 
a homozygous mutation in GNRHR (p.Q106R hom and p.R262Q hom respectively). All 
other cases, when queried for their respective gene, did not have a variant in that gene. 
One of the advantages to using SNP genotyping is it allows us to preview information in 
Table 2: Number of Cases and Controls with ROHs that Overlap Known IGD Genes. 
(Balasubramanian 2003). Numbers of cases and controls are standardized to per 500 individuals for an 
accurate comparison taking into account population size. 
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the non-coding regions of the genome. Our current understanding about variants found in 
the non-coding regions is still in its infancy; however, one useful place to start to 
understand these potential defects is looking at eQTLs or expression quantitative trait loci 
that can theoretically cause expression changes in their target gene. The Gene eQTL 
Visualizer in GTEx was therefore used to determine the locations of cis-eQTLs for the 26 
known genes that affected expression levels in any brain tissue or in the pituitary. 19/26 
genes had eQTLs that affected expression in brain tissue or in the pituitary. The total 
genomic location that included all eQTLs for a specific gene in the tissue specified, the 
largest positive effect size or largest negative effect size or both, if that applied, of an 
eQTL within that area, the total number of eQTLs within the region, and the number of 
cases/controls with ROHs that span all of the region were recorded as shown in Table 3.  
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Table 3: Locations of eQTLs in Known IGD Genes seen in Neuronal or Pituitary Tissue Identified 
through GTEx and the Number of Cases and Controls with an ROH that Spans the Area eQTL 
regions are provided by GTEx. (GETx 2017) Numbers of cases and controls are standardized to per 500 
individuals for an accurate comparison taking into account population size. 
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Homozygosity Mapping Analysis in Novel Regions of the Genome in the European  
Only Cohort  
 
Four different chromosomal regions in the genome with a unique region of homozygous 
SNPs seen only in cases (probands) and not in controls were found: one on chromosome 
3, one on chromosome 4, one on chromosome 6 and on chromosome 7. Individual 
probands who possessed an ROH that covered one of these unique areas were assessed as 
shown in Table 4.  
The UCSC Genome 
Browser found 1 coding 
gene in the unique region 
124,810,960 on 
chromosome 3 called 
Sodium Channel and 
Clathrin Linker 1 
(SLC12A8). All four 
probands in table 4 that 
have a ROH spanning this 
area were queried in 
GEMINI for potential 
mutations in the coding areas of these genes but none of the four individuals had a 
homozygous variant in this gene. The UCSC Genome Browser also failed to find any 
coding genes within the unique region 82,547,364-82,587,050 on chromosome 4; 
Figure 13: Coding Genes within the Unique Regions shared by 
Cases Only 
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however, they did find a long intergenic non-coding RNA, RP11-689K5.3 that has its 
highest median expression in the pituitary (GTEx 2017). The UCSC Genome Browser 
found one coding gene within the unique region 96,296,327-96,846,975 on chromosome 
6 called fucosyltransferase 9 (FUT9). All four IGD probands in Table 4 with an ROH 
spanning the ROH were queried in Gemini for homozygous variants in this gene but none 
were found. Three non-coding transcripts were also found in this region: A pseudogene, 
RN752797P, with highest median expression in subcutaneous adipose (GTEx 2017), a 
pseudogene, KRT18P50 with its highest median expression in subcutaneous adipose 
(GTEx 2017), and an antisense RNA, UFL1-AS1, with its highest median expression in 
the testis (GTEx 2017). Finally, the UCSC Genome Browser found 2 coding genes within 
the unique region of 143,053,713-143,080,060 on chromosome 7: a family with sequence 
similarity in 131 member B (FAM131B) and zyxin (ZXY) . None of the six probands in 
Table 4 with a ROH overlapping this region had a homozygous variant in either coding 
gene. Two non-coding transcripts within this unique region were also found: A long 
intergenic non-coding RNA, RP11-563K23.1, whose highest median expression occurs in 
the anterior cingulate cortex of the brain (GETx 2017) and an antisense RNA, 
AC093673.5, with the highest median expression in the uterus (GETx 2017). More 
information about the coding genes found in any of the four unique regions is found in 
Figure 13. 
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Table 4: Four Unique Homozygous SNP Regions Shared by Four or more Cases and no Controls.  
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DISCUSSION 
ROH Burden Analysis in the European Only Cohort 
In this study, there were no significant findings to conclude that autozygosity is a risk 
factor for IGD. In fact, the data appears to show the opposite trend where, in general, the 
controls seem to have more ROHs, both when looking at their number and their length, 
than the cases. These results, however, do not rule out the hypothesis that autozygosity is 
a risk factor for IGD. Several limitations to this study include the small size of our patient 
population, the density of the SNP chips available, the limitation of the control data set, 
and the lack of ROH coverage of the X chromosome.  
Due to the rarity of our disease model and its reproductive phenotype’s negative 
selection on a population basis, the small effect size in an outbred population has proven 
to be challenging.  To gain significant results from these populations, it has been shown 
that sample sizes need to be around 12,000-65,000 individuals (Keller 2011). Our 
population size was 653 probands. Second, the density of the PsychChip used for this 
analysis was 264,522 SNPs whereas the optimal standard density of a currently available 
microarray chip is now closer to 1 million SNPs (Ceballos 2018). With increasing 
densities of the SNP chip, higher quality call rates for ROHs can be achieved. For this 
study, the QC was stringent since two different versions of the PsychArray were used and 
eventually merged together. Also, different batches within a single version where 
genotyped at different times and then merged together, which could lead to differences in 
call rates, therefore, a considerable number of SNPs in this analysis were lost. Third, the 
control data set had its initial QC done at The Broad Institute whereas the cases initial QC 
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was performed at the REU (see methods), which could have caused variation in the QC 
of the cases versus the controls. Also, these controls come from The Schizophrenia 
Psychiatric Genome-Wide Association Study; thus there might be a chance that 
unaffected schizophrenic family members are in the control population data set. While 
there have been mixed results whether schizophrenics have an increased burden of ROH 
(Keller 2012), several studies, including Keller et al 2012, have shown that there is an 
increased burden of ROH in this population. If this is true and schizophrenic family 
members are in the control group, there could be an over inflation of the length and 
number of ROHs in the control population that might obscure differences in the IGD 
population. Finally, the X chromosome contains a higher rate of ROHs due to its low 
recombination rate (Curtis 2008) and would therefore be an ideal location where ROH 
would uncover novel causal variation, especially since one of our known IGD genes, 
ANOS1 (KAL1) is located on the X chromosome. There is, however, a low SNP density 
on the X chromosome leaving it much harder to interpret (Ceballos 2018). Along with the 
stated limitations to this study, as already mentioned above but in a slightly different 
context, another reason the hypothesis of autozygosity being a risk factor for IGD cannot 
be ruled out is that in other disease models, such as schizophrenia, the results on whether 
there is a significant effect of autozygosity in their disease have been mixed with several 
studies finding a significance and others not (Keller 2012). These results shows that our 
understanding of ROHs in outbred populations, as well as our detection methods, can still 
be improved. 
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Homozygosity Mapping Analysis on Known Genes and their Predicted Regulatory 
Sites in the European Only Cohort 
It was unlikely that novel variants in the coding regions of known genes would be 
uncovered using homozygosity mapping since whole exome sequencing has been 
performed on all the individuals that had undergone SNP genotyping in this analysis in 
the REU cohort. However, uncovering two IGD cohort probands with ROHs spanning 
the genomic location of the known IGD causing gene, GNRHR, both of whom turned out 
to also be homozygous for a variant in GNRHR, validates the approaches we employed to 
detect the ROHs. This validation still holds despite the fact that these homozygous 
mutations were already known in these individuals, since the individuals were uncovered 
using an unbiased method, where no indications of known gene variation were known 
when searching for individuals with ROHs that overlapped the region of interest. It is 
only after the individual IDs were found that their genetic variation was confirmed.  
The advantage to using SNP genotyping analysis vs. whole exome sequencing 
(WES), however, lies not in finding defects in the coding region where WES is clearly 
superior. Rather, surfacing defects in the non-coding region of the genome is where ROH 
has its greatest value. The majority of the SNPs genotyped (80+ %) lie within the non-
coding regions of the genome. These regions in the non-coding domains of the human 
genome are predicted to influence the expression of our known genes and currently are 
not accessible via WES. Therefore, this method provides a way to examine potential 
disease causing variants within both the non-coding regions and the eQTL domains of 
those genes. Typical of Mendelian conditions, many known IGD genes exhibit variable 
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penetrance/expressivity defined as whether the gene mutation causes the disease or not 
(penetrance) or to what extent the phenotype is expressed (expressivity) either within 
their family or across other IGD families. Expression quantitative trait loci (eQTL’s) 
have been shown to account for at least some of this variability (Castel 2017). While it is 
still problematic to fully interpret what it means for a certain number of cases and 
controls to overlap a region of interest, it is interesting to note that there is an overall 
trend, when looking at Tables 2 and 3 where, when the numbers of cases and controls 
with ROHs spanning a region of interest is standardized to per 500 individuals, the cases 
have an overall higher representation of ROHs in these regions compared to the controls. 
With the decreasing price of next generation sequencing, it is increasingly feasible to 
perform whole genome sequencing (WGS) on individuals within disease cohorts. New 
pipelines are being rapidly developed to both manage and interpret these results and our 
understanding keeps improving as well. It is crucial for the complete understanding of 
human genetics to begin examining the non-coding region since 98% of the human 
genome is non-coding (Iulio 2018). Therefore, prioritizing the sequencing of certain 
individual’s genomes that already have areas of interest with potential disease-causing 
variations within their non-coding region is a good place to start. The cases that overlap 
eQTL regions of known genes (roughly 194/653) would be high on this list.  
Homozygosity Mapping Analysis in Novel Regions of the Genome in the European 
Only Cohort 
Four regions of homozygous SNPs were found in which 4 or more cases had regions of 
ROHs that overlapped while no controls overlapped the region. This discovery analysis 
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eliminated the uncertainty in interpreting what it means for a control sample to overlap an 
area of interest thus making these 4 areas particularly intriguing. Some of these 4 
individuals (Table 4) have genetic variation in a known IGD gene. However, due to the 
high levels of incomplete penetrance and incomplete expressivity that are frequently 
observed in our known genes, these known genetic variants certainty do not have to be 
the cause or the only cause of the disease. As our group previously documented, 
oligogenicity is prevalent in IGD (Sykiotis 2010; Balasubramanian 2010) and it is likely 
that another known gene variant could be working in synergy with another variant, either 
in a coding gene or non-coding regulatory region. While no case had a homozygous 
variant in a coding gene within the unique area of interest in the genome, this lack does 
not preclude contributory variation within the non-coding region of these unique areas, 
again underscoring the importance of understanding how to interpret these regions and 
also the contributing knowledge WGS will surely provide us. Cases overlapping these 
areas of interest would also be considered higher priority cases for whole genome 
sequencing.  
Alternative ROH Detection Methods 
Two main methods have been used to detect ROH: observational genotype-counting and 
model-based approaches (Ceballos 2018). The approach used in this study was an 
observational approach using PLINK (Purcell 2007). PLINK employs a sliding window 
that checks for the amount of homozygous SNPs within a given window and will call a 
ROH based on the criteria specified, whether it be no heterozygous SNPs allowed in a 
ROH, the minimum and maximum amount of SNPs that define a ROH, etc. A model-
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based approach can be done through programs such as Beagle (Ceballos 2018, Browning 
2013) that uses a hidden Markov model (HMM) to detect ROHs. PLINK, however, has 
been shown to outperform other models such as Beagle (Howrigan 2011), and was 
therefore the best program to use for this study.   
Next Steps 
Homozygosity mapping is a useful tool for detecting Mendelian disease variants, where a 
variation in a single gene gives rise to a phenotype that can be passed from parent to 
offspring. Complex Trait Genetics involves variations in multiple genes that can interact 
with the environment. While IGD is historically thought of as a Mendelian disease 
(Balasubramanian 2012), it is becoming clearer that there should be less of a divide in 
thinking between the two genetic disease approaches; rather a more holistic approach that 
combines both Mendelian disease and complex trait disease methods should be 
considered and might be more profitable to employ. Genome wide association studies 
(GWAS) uses SNP markers to identify variants associated with a given trait in an 
unbiased manner and have been extensively used and quite successful in identifying 
variants in complex common traits (Verma 2018). The QC’ed SNPChip dataset created in 
this study will be used as the platform in an IGD GWAS study.  
     Another method that uses this SNPChip platform as a marker is a transmission 
disequilibrium test (TDT). A TDT is a family-based association test based on linkage that 
tests for seemingly overtransmission of a disease-causing allele to an affected individual 
from his/her parents. The REU IGD cohort, being one of the largest cohorts for this rare 
 41 
disease in the world, has a fair amount of genotyped affected individuals whose parents 
are also genotyped (termed trios) that will be used for this analysis.   
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